Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $18.1 million.

  • Monte Rosa Therapeutics' Share-based Compensation rose 1.91% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 7.30%. This contributed to the annual value of $18.1 million for FY2024, which is 8.74% up from last year.
  • Monte Rosa Therapeutics' Share-based Compensation amounted to $18.1 million in FY2024, which was up 8.74% from $16.7 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Share-based Compensation high stood at $18.1 million for FY2024, and its period low was $354,000 during FY2020.
  • In the last 3 years, Monte Rosa Therapeutics' Share-based Compensation had a median value of $16.7 million in 2023 and averaged $15.5 million.
  • Data for Monte Rosa Therapeutics' Share-based Compensation shows a peak YoY soared of 1,368.93% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Share-based Compensation stood at $354,000 in 2020, then soared by 1,368.93% to $5.2 million in 2021, then spiked by 124.31% to $11.7 million in 2022, then skyrocketed by 42.91% to $16.7 million in 2023, then rose by 8.74% to $18.1 million in 2024.